Abstract
In a prospective study we examined 38 patients with primary bronchogenic carcinoma to validate the use of indium- I 11 pentetreotide (IPT) as a diagnostic tool. Of these 38 patients, 25 had small cell lung cancer (SCLC) and 13, non-small cell lung cancer (NSCLC). The aim of the study was to investigate whether (a) the disease can be reliably detected, (b) IPT allows differentiation between SCLC and NSCLC and (c) IPT provides further information on metastatic disease. After giving their informed consent the patients were injected and imaged 4 and 24 h later using a planar whole-body technique. In addition single-photon emission tomography of the thorax and, if necessary, other areas of the body was performed at 24 h. In the 25 patients with SCLC 22 sites of primary tumour were correctly identified (true-positive, TP); one was false-negative (FN) and two were true-negative (TN), the patients being in full remission. Metastases were correctly identified in ten instances (lung,bone and brain), while the findings were FN in five cases. An additional six FN findings resulted in the area of the upper abdomen due to the physiological uptake in the liver, spleen and kidneys. In the 13 patients with NSCLC, ten findings were TP and 3 FN with respect to the primary tumour. Two FNs were squamous cell carcinoma, and one, adenocarcinoma. Metastases were TP in nine cases and FN in one. We therefore conclude: (1) IPT is a highly sensitive method for the detection of primary bronchogenic carcinoma, and in particular for SCLC, (2) differentiation between SCLC and NSCLC cannot be achieved and (3) the method is of limited use in the search for metastatic disease. Compared with the conventional imaging modalities like X-ray, CT and bone scintigraphy, IPT provides only a small amount of additional diagnostic information.
Similar content being viewed by others
References
Leonard RCF. Small cell lung cancer.Br J Cancer 1989; 59: 487–490.
Itch K, Takekawa H, Tsukamoto E, Nagao K, Nakada K, Abe S, Kawakami Y, Furudate, M. Single photon emission computed tomography using 201-T1: comparison with 67-Ga citrate and 99mTc labelled hexamethylpropyleneamine-oxime.Ann Nucl Med 1992; 6: 253–260.
Sehweil AM, McKillop JH, Milroy R, Sayed MA, Ziada G, Banham SW, Davidson KG, Ragib A, Omar YT, AbdelDayem HM. 201-T1 scintigraphy in the staging of lung cancer, breast cancer and lymphoma.Nucl Med Commun 1990; 11: 263–269.
Duman Y, Burak Z, Erdem S, Tufan M, Ünlü M, Haydarogullari A, Özkök S, Anacak Y, Erding E. The value and limitations of 201-T1 scintigraphy in the evaluation of lung lesions and post-therapy follow up of primary lung carcinoma.Nucl Med Commun 1993; 14: 446–453.
Wadler S, Tai K, Chervu LR, Rafii S, Landau L, Blaufox MD, Wiernik PH. Iodine-131 MIBG scintigraphy in small cell lung cancer.Eur J Nucl Med 1989; 15: 108–110.
Osei-Bonsu A, Kokoschka EM, Ulrich W, Sinzinger H. 131Metaiodobenzylguanidine (mIBG) for bronchial oat cell cancer and melanoma detection.Eur J Nucl Med 1989; 15: 629–631.
Biggi A, Buccheri G, Ferrigno D, Viglietti A, Farinelli MG, Comino A, Leone A, Quaranta M, Taviani M. Detection of suspected primary lung cancer by scintigraphy with indium111 anticarcinoembryonic antigen monoclonal antibodies (type F023C5).J Nucl Med 1991; 32: 2064–2068.
Krishnamurthy S, Morris JF, Antonovic R, Ahmed A, Galey WT, Duncan C, Krishnamurthy GT. Evaluation of primary lung cancer with indium l 11 anti-carcinoembryonic antigen (type ZCE-025) monoclonal antibody.Cancer 1990; 65: 458–465.
Breitz HB, Sullivan K, Nelp WB. Imaging lung cancer with radiolabelled antibodies.Semin Nucl Med 1993; 23: 127–132.
Reubi JC, Waser B, Sheppard M, Macaulay V. Somatostatin receptors are present in small-cell but not in non-small-cell primary lung carcinomas: relationship to EGF-receptors.Int J Cancer 1990; 45: 269–274.
Sagman U, Mullen JB, Kovacs K, Kerbel R, Ginsberg R, Reubi JC. Identification of somatostatin receptors in human small cell lung carcinoma.Cancer 1990; 66: 2129–2133.
Taylor JE, Coy DH, Moreau JP. High affinity binding of [125I-Tyr-1 1]somatostatin-14 to human small cell lung carcinoma (NCI-H69).Life Sci 1988; 43: 421–427.
Bepler G, Rotsch M, Jaques G, Haeder M, Heymanns J, Hartogh G, Kiefer P, Havemann K. Peptides and growth factors in smal 1 cell lung cancer: production, binding sites and growths effects.J Cancer Res Clin Oncol 1988; 144: 235–244.
Taylor JE, Moreau JP, Baptiste L, Moody TW. Octapeptide analogues of somatostatin inhibit the clonal growth and vaso-active intestinal peptide-stimulated cyclic AMP formation in human small cell lung cancer cells.Peptides 1991; 12: 839–843.
Kwekkeboom D, Krenning E, Bakker WH, Oei HY, Splinter TAW, Kho GS, Lamberts SWJ. Radioiodinated somatostatin analog scintigraphy in small cell lung cancer.J Nucl Med 1991; 32: 1845–1848.
Krenning EP, Bakker WH, Knooij PPM, Breeman WAP, Oei HY, de Jong M, Reubi JC, Visser TJ, Bruns C, Kwekkeboom DJ, Reijs AEM, van Hagen PM, Koper JW Lamberts SWJ. Somatostatin receptor scintigraphy with indium-1 l l DTPA-DPhe-l-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide.J Nucl Med 1992; 33: 652–658.
Lamberts SWJ, Krenning EP, Reubi JC. The role of somatostatin and its analogs in the diagnosis and treatment of tumours.Endocrine Rev 1991; 12: 450–482.
Linnoila RI, Mulshine JL, Steinberg SM, Funa K, Matthews MJ, Cotelingham JD, Gazdar AF. Neuroendocrine differentiation in endocrine and nonendocrine lung carcinomas.Am J Clin Pathol 1988; 90: 641–652.
Strauss LG, Conti PS. The applications of PET in clinical oncology.J Nucl Med 1991; 32: 623–648.
Macauly VM, Smith IE, Everard MJ, Teale JD, Reubi JC, Milar JL. Experimental and clinical studies with somatostatin analogue octreotide in small cell lung cancer.Br J Cancer 1991; 64: 451–456.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kirsch, CM., von Pawel, J., Grau, I. et al. Indium-111 pentetreotide in the diagnostic work-up of patients with bronchogenic carcinoma. Eur J Nucl Med 21, 1318–1325 (1994). https://doi.org/10.1007/BF02426696
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02426696